Inhibitors of 11β-HSD1: A Potential Treatment for the Metabolic Syndrome

被引：19

作者：

Jean, David J. St., Jr. ^{[1
]}

Wang, Minghan ^{[1
]}

Fotsch, Christopher ^{[1
]}

机构：

[1] Amgen Inc, Dept Med Chem, Thousand Oaks, CA 91320 USA

来源：

CURRENT TOPICS IN MEDICINAL CHEMISTRY | 2008年 / 8卷 / 17期

关键词：

11 beta-hydroxysteroid dehydrogenase; glucocorticoid excess; cortisol; Cushing's syndrome; HPA axis; metabolic syndrome;

D O I：

10.2174/156802608786413528

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) is the enzyme that converts cortisone to cortisol. A growing body of evidence suggests that selective inhibition of 11 beta-HSD1 could potentially treat the metabolic syndrome. This review provides an overview of compounds reported to have in vivo inhibitory activity against this enzyme. A major focus of this review is Amgen's 11 beta-HSD1 program which includes a variety of in vivo data for a lead compound from our thiazolone class of inhibitors. Finally, an update on the current known clinical data is discussed.

引用

页码：1508 / 1523

页数：16

共 50 条

[1] Discovery of potent and selective inhibitors of 11β-HSD1 for the treatment of metabolic syndrome
Richards, Steven
Sorensen, Bryan
Jae, Hwan-Soo
Winn, Marty
Chen, Yixian
Wang, Jiahong
Fung, Steven
Monzon, Katina
Frevert, Ernst U.
Jacobson, Peer
Sham, Hing
Link, J. T.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (24) : 6241 - 6245
[2] Evaluation of selective inhibitors of 11β-HSD1 for the treatment of hypertension
Bauman, David R.
Whitehead, Alan
Contino, Lisa C.
Cui, Jisong
Garcia-Calvo, Margarita
Gu, Xin
Kevin, Nancy
Ma, Xiuying
Pai, Lee-yuh
Shah, Kashmira
Shen, Xiaolan
Stribling, Sloan
Zokian, Hratch J.
Metzger, Joe
Shevell, Diane E.
Waddell, Sherman T.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (12) : 3650 - 3653
[3] MEDI 53-Synthesis and biologic evaluation of selective inhibitors of 11β-HSD1 as a potential treatment for metabolic disorders
Neelamkavil, Santhosh F.
Boyle, Craig D.
Chackalamannil, Samuel
Baker, Hana
Kowalski, Timothy
Zhang, Lili
Terracina, Giuseppe
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 234
[4] Development of 11β-HSD1 inhibitors for the treatment of type 2 diabetes
Hale, Clarence
Wang, Minghan
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2008, 8 (07) : 702 - 710
[5] Molecular screening of the 11β-HSD1 gene in men characterized by the metabolic syndrome
Robitaille, J
Brouillette, C
Houde, A
Després, JP
Tchernof, A
Vohl, MC
OBESITY RESEARCH, 2004, 12 (10): : 1570 - 1575
[6] Recent advances in the discovery of 11β-HSD1 inhibitors
Boyle, Craig D.
CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2008, 11 (04) : 495 - 511
[7] Structure Based Design of 11β-HSD1 Inhibitors
Singh, Suresh B.
Tice, Colin M.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2010, 11 (07) : 779 - 791
[8] Azabicyclic sulfonamides as potent 11β-HSD1 inhibitors
Shah, Unmesh
Boyle, Craig D.
Chackalamannil, Samuel
Baker, Hana
Kowalski, Timothy
Lee, Julie
Terracina, Giuseppe
Zhang, Lili
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (05) : 1551 - 1554
[9] 11β-HSD1 Inhibitors from Walsura cochinchinensis
Han, Mei-Ling
Shen, Yu
Wang, Guo-Cai
Leng, Ying
Zhang, Hua
Yue, Jian-Min
JOURNAL OF NATURAL PRODUCTS, 2013, 76 (07): : 1319 - 1327
[10] Bicyclo[2.2.2]octyltriazole inhibitors of 11β-HSD1
Waddell, Sherman T.
Gu, Xin
Santorelli, Gina
Graham, Donald
Balkovec, James
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 231

← 1 2 3 4 5 →